信立泰(002294.SZ):控股股東擬轉讓5%的股份予中信里昂資管
格隆匯 9 月 1日丨信立泰(002294.SZ)公佈,公司的控股股東信立泰藥業有限公司(“香港信立泰”)通過協議轉讓的方式,將合計持有的公司5230.08萬股無限售流通股(佔公司總股本的5%)轉讓給中信里昂資產管理有限公司(CLSA Asset Management Limited)。此次轉讓價格為33.94元/股,轉讓總價為人民幣17.75億元。
此次協議轉讓股份前,香港信立泰持有公司股份687,580,180股,佔公司總股本的65.73%。轉讓完成後,香港信立泰持有公司股份635,279,380股,佔公司總股份的60.73%。
此次轉讓前,中信里昂資產管理有限公司未持有公司股份。轉讓完成後,中信里昂資產管理有限公司持有公司股份5230.08萬股,佔公司總股本的5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.